Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux, Christoph Faul, Helmut Diedrich, Max S. Topp, Monika Brüggemann, Heinz-August Horst, Violaine Havelange, Julia Stieglmaier, Hendrik Wessels, Vincent Haddad, Jonathan E. Benjamin, Gerhard Zugmaier, Dirk Nagorsen, Ralf C. Bargou

Blood (2018) 131 (14): 1522–1531.

https://doi.org/10.1182/blood-2017-08-798322

Published: 2018

Includes: Supplemental data

Journal Articles

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Andreas Viardot, Marie-Elisabeth Goebeler, Georg Hess, Svenja Neumann, Michael Pfreundschuh, Nicole Adrian, Florian Zettl, Martin Libicher, Cyrus Sayehli, Julia Stieglmaier, Alicia Zhang, Dirk Nagorsen, Ralf C. Bargou

Blood (2016) 127 (11): 1410–1416.

https://doi.org/10.1182/blood-2015-06-651380

Published: 2016

Includes: Supplemental data

Journal Articles

Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Nicola Gökbuget, MD, Hervé Dombret, MDPhD, Massimiliano Bonifacio, MD, Albrecht Reichle, MD, Carlos Graux, MDPhD, Christoph Faul, MD, Helmut Diedrich, MD, Max S. Topp, MD, Monika Brüggemann, MD, Heinz A. Horst, MD PhD, Julia Stieglmaier, PhD, Hendrik Wessels, MD, Vincent Haddad, MSc, Gerhard Zugmaier, MD, Dirk Nagorsen, MD, Ralf C Bargou, MD

Blood (2015) 126 (23): 680.

https://doi.org/10.1182/blood.V126.23.680.680

Published: 2015

Journal Articles

Expression of Novel Immune Checkpoint Molecules PVR and PVRL2 Confers a Negative Prognosis to Patients with Acute Myeloid Leukemia and Their Blockade Augments T-Cell Mediated Lysis of AML Cells Alone or in Combination with the BiTE ® Antibody Construct AMG 330

Hauke Stamm, MSc, Felix Klingler, cand. MD, Daniela Pende, MD, Eik Vettorazzi, MSc, Michael Heuser, MD, Ulrike Mock, PhD, Carsten Bokemeyer, MD, Roman Kischel, MD, Sabine Stienen, PhD, Matthias Friedrich, PhD, Michael Lutteropp, PhD, Dirk Nagorsen, MD, Jasmin Wellbrock, PhD, Walter Fiedler, MD

Blood (2015) 126 (23): 789.

https://doi.org/10.1182/blood.V126.23.789.789

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE ® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Anthony Stein, Max S. Topp, Nicola Goekbuget, Ralf C. Bargou, Hervé Dombret, Adele K. Fielding, Richard A. Larson, Alessandro Rambaldi, Gary Schiller, MD, Gerhard Zugmaier, Catherine Jia, Tapan Maniar, Birgit Huber, Dirk Nagorsen, Hagop Kantarjian, Stephen J. Forman

Blood (2014) 124 (21): 965.

https://doi.org/10.1182/blood.V124.21.965.965

Published: 2014

Journal Articles

An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE ® Antibody Construct Blinatumomab

Nicola Goekbuget, Hagop Kantarjian, Monika Brüggemann, Anthony Stein, Ralf C. Bargou, Hervé Dombret, Adele K. Fielding, Leonard Heffner, Françoise Rigal-Huguet, Mark Litzow, Susan O'Brien, Gerhard Zugmaier, Catherine Jia, Tapan Maniar, Birgit Huber, Dirk Nagorsen, Stephen J. Forman, Max S. Topp

Blood (2014) 124 (21): 3704.

https://doi.org/10.1182/blood.V124.21.3704.3704

Published: 2014

Journal Articles

BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE ® ) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL)

Nicola Goekbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux, Violaine Havelange, Eike C. Buss, Christoph Faul, Monika Bruggemann, Arnold Ganser, Julia Stieglmaier, Hendrik Wessels, Vincent Haddad, Gerhard Zugmaier, Dirk Nagorsen, Ralf C. Bargou

Blood (2014) 124 (21): 379.

https://doi.org/10.1182/blood.V124.21.379.379

Published: 2014

Journal Articles

Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma with the Bispecific T-Cell Engager (BiTE ® ) Antibody Construct Blinatumomab: Primary Analysis Results from an Open-Label, Phase 2 Study

Andreas Viardot, Mariele Goebeler, Georg Hess, Svenja Neumann, Michael Pfreundschuh, Nicole Adrian, Florian Zettl, Martin Libicher, Evelyn Degenhard, Julia Stieglmaier, Alicia Zhang, Dirk Nagorsen, Ralf C. Bargou

Blood (2014) 124 (21): 4460.

https://doi.org/10.1182/blood.V124.21.4460.4460

Published: 2014

Journal Articles

Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE ® ) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Andreas Viardot, Mariele Goebeler, Michael Pfreundschuh, Nicole Adrian, Martin Libicher, Evelyn Degenhard, Julia Stieglmaier, Alicia Zhang, Dirk Nagorsen, Ralf C. Bargou

Blood (2013) 122 (21): 1811.

https://doi.org/10.1182/blood.V122.21.1811.1811

Published: 2013

Journal Articles

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Blood (2012) 120 (26): 5185–5187.

https://doi.org/10.1182/blood-2012-07-441030

Published: 2012

Journal Articles

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Matthias Klinger, Christian Brandl, Gerhard Zugmaier, Youssef Hijazi, Ralf C. Bargou, Max S. Topp, Nicola Gökbuget, Svenja Neumann, Mariele Goebeler, Andreas Viardot, Matthias Stelljes, Monika Brüggemann, Dieter Hoelzer, Evelyn Degenhard, Dirk Nagorsen, Patrick A. Baeuerle, Andreas Wolf, Peter Kufer

Blood (2012) 119 (26): 6226–6233.

https://doi.org/10.1182/blood-2012-01-400515

Published: 2012

Includes: Supplemental data

Journal Articles

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

Blood (2011) 118 (21): 1637.

https://doi.org/10.1182/blood.V118.21.1637.1637

Published: 2011

Journal Articles

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 174.

https://doi.org/10.1182/blood.V116.21.174.174

Published: 2010

Journal Articles

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m 2 /d Is Tolerable and Highly Effective

Andreas Viardot, MD, Mariele Goebeler, MD, Jurgen S. Scheele, MD, PhD, Gerhard Zugmaier, MD, Richard Noppeney, MD, Stefan Knop, MD, Max S Topp, MD, Dirk Nagorsen, MD, Matthias Klinger, PhD, Margit Schmidt, PhD, Petra Klappers, Peter Kufer, MD, Hermann Einsele, MD, Ralf Bargou, MD

Blood (2010) 116 (21): 2880.

https://doi.org/10.1182/blood.V116.21.2880.2880

Published: 2010

Journal Articles

Identification of a Predictive Factor for Reversible Neurological Adverse Events in a Subset of Non-Hodgkin Lymphoma Patients Treated with CD19-Specific BiTE ® Antibody Blinatumomab.

Gerhard Zugmaier, Dirk Nagorsen, Matthias Klinger, Ralf C Bargou, Mariele Goebeler, Andreas Viardot, Patrick A Baeuerle, Peter Kufer

Blood (2009) 114 (22): 4793.

https://doi.org/10.1182/blood.V114.22.4793.4793

Published: 2009

Journal Articles

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Dirk Nagorsen, Gerhard Zugmaier, Peter Kufer, Matthias Klinger, Andreas Viardot, Mariele Goebeler, Margit Schmidt, Petra Klappers, Andreas Wolf, Christian Brandl, Patrick A Baeuerle, Ralf C Bargou

Blood (2009) 114 (22): 4798.

https://doi.org/10.1182/blood.V114.22.4798.4798

Published: 2009

Journal Articles

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Blood (2009) 114 (22): 840.

https://doi.org/10.1182/blood.V114.22.840.840

Published: 2009

Journal Articles

Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m 2 /d of BiTE® Antibody Blinatumomab.

Dirk Nagorsen, Gerhard Zugmaier, Andreas Viardot, Mariele Goebeler, Richard Noppeney, Margit Schmidt, Petra Klappers, Patrick A Baeuerle, Peter Kufer, Ralf C Bargou

Blood (2009) 114 (22): 2723.

https://doi.org/10.1182/blood.V114.22.2723.2723

Published: 2009

Journal Articles

Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL

Ralf C Bargou, MD, Peter Kufer, MD, Mariele Goebeler, MD, Stefan Knop, MD, Hermann Einsele, MD, Richard Noppeney, MD, Andreas Viardot, MD, Patrick A Baeuerle, PhD, Carsten Reinhardt, MD, Margit Schmidt, PhD, Petra Klappers, Dirk Nagorsen, MD, Gerhard Zugmaier, MD

Blood (2008) 112 (11): 267.

https://doi.org/10.1182/blood.V112.11.267.267

Published: 2008

Journal Articles

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

Max Topp, MD, Nikola Goekbuget, MD, Peter Kufer, MD, Gerhard Zugmaier, MD, Evelyn Degenhard, Svenja Neumann, MD, Heinz A Horst, MD, Andreas Viardot, MD, Mathias Schmid, MD, Oliver G. Ottmann, MD, Margit Schmidt, PhD, Carsten Reinhardt, MD, Patrick A Baeuerle, PhD, Dirk Nagorsen, MD, Dieter Hoelzer, MD, PhD, Ralf C. Bargou, MD

Blood (2008) 112 (11): 1926.

https://doi.org/10.1182/blood.V112.11.1926.1926

Published: 2008

NARROW

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Expression of Novel Immune Checkpoint Molecules PVR and PVRL2 Confers a Negative Prognosis to Patients with Acute Myeloid Leukemia and Their Blockade Augments T-Cell Mediated Lysis of AML Cells Alone or in Combination with the BiTE ® Antibody Construct AMG 330

Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE ® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE ® Antibody Construct Blinatumomab

BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE ® ) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL)

Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma with the Bispecific T-Cell Engager (BiTE ® ) Antibody Construct Blinatumomab: Primary Analysis Results from an Open-Label, Phase 2 Study

Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE ® ) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m 2 /d Is Tolerable and Highly Effective

Identification of a Predictive Factor for Reversible Neurological Adverse Events in a Subset of Non-Hodgkin Lymphoma Patients Treated with CD19-Specific BiTE ® Antibody Blinatumomab.

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m 2 /d of BiTE® Antibody Blinatumomab.

Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only